Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy
Main Authors: | David García‐Bernal, Edward Richardson, Israel Vlodavsky, Carmelo Carlo‐Stella, Massimo Iacobelli, Rubén Jara, Paul G. Richardson, Jose M. Moraleda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | eJHaem |
Online Access: | https://doi.org/10.1002/jha2.198 |
Similar Items
-
The use of defibrotide in blood and marrow transplantation
by: Paul G. Richardson, et al.
Published: (2018-06-01) -
Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide
by: Hui Shi, et al.
Published: (2021-09-01) -
Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control
by: Annalisa Ruggeri, et al.
Published: (2024-05-01) -
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
by: Antonio Palumbo, et al.
Published: (2010-07-01) -
Pathogenesis of respiratory failure in COVID-19 due to coagulopathy and endothelial dysfunction
by: T. O. Burdienko
Published: (2024-09-01)